Omada Health Inc (NASDAQ:OMDA) delivered quarterly results that significantly exceeded Wall Street's expectations, propelling its shares higher in after-hours trading. The virtual healthcare provider reported strong top-line growth and achieved a critical milestone of profitability, a combination that resonated positively with investors.
Earnings and Revenue Beat
The company's fourth-quarter performance for 2025 showcased robust execution, with both revenue and earnings per share coming in well above analyst forecasts.
- Revenue: Reported at $75.8 million, a 58% increase year-over-year. This comfortably surpassed the consensus estimate of approximately $71.1 million.
- Earnings Per Share (Non-GAAP): Reported at $0.13, a stark contrast to the estimated loss of $0.05 per share. This swing to positive earnings represents a significant inflection point for the company.
The strength was not confined to the quarter alone. For the full year 2025, Omada reported revenue of $260.2 million, up 53% from the prior year.
Market Reaction and Strategic Milestones
The market's immediate reaction was decisively positive, with shares rising nearly 6% in after-hours trading following the announcement. This move extends a period of recent strength for the stock. The positive sentiment is likely driven by two key factors from the earnings report: the substantial earnings beat and the achievement of full-year positive Adjusted EBITDA.
Beyond the financial figures, the press release highlighted several strategic pillars that underpin Omada's growth:
- Explosive Member Growth: Total members reached 886,000 at year-end, a 55% increase year-over-year, demonstrating strong market adoption.
- GLP-1 Leadership: The company has now supported over 150,000 members on GLP-1 medications, triple the number from the end of 2024. It also announced "GLP-1 Flex Care," a new offering designed to give employers flexible pathways to provide access to these treatments alongside Omada's behavioral support.
- Path to Profitability: The company achieved a net income of $5 million in the fourth quarter, compared to a loss of $8 million in the prior-year period. For the full year, it delivered positive Adjusted EBITDA of $6 million, a notable improvement from a $29 million loss in 2024.
- Strengthened Balance Sheet: Cash and cash equivalents stood at $222 million at year-end, providing a solid foundation for continued investment and growth.
Forward Guidance Versus Estimates
Management provided an outlook for 2026 that sets a trajectory for continued, albeit moderating, growth. The company expects revenue in the range of $312 million to $322 million, with the midpoint representing 22% growth over 2025.
- Revenue Guidance: The midpoint of Omada's 2026 revenue guidance ($317 million) is marginally below the current analyst sales estimate of approximately $317.6 million, suggesting expectations are largely aligned.
- Earnings Context: While the company provided an Adjusted EBITDA outlook of $7 to $15 million, it did not provide GAAP net income or EPS guidance. The analyst consensus for Non-GAAP EPS in 2026 currently stands at a loss of $0.07. Omada's profitability in Q4 and its positive EBITDA guide imply the company is on a path that could challenge these full-year loss estimates if the momentum continues.
Conclusion
Omada Health's fourth-quarter report marks a pivotal moment, transitioning from a high-growth, loss-making enterprise to one demonstrating both robust expansion and improving profitability. The double beat on revenue and earnings, coupled with strong member growth and strategic positioning in the high-demand GLP-1 support market, validates its business model. The market's positive reaction reflects approval of this financial inflection point. Investors will now watch to see if the company can sustain its growth rate while continuing to expand its profitability margins in the coming year.
For a detailed look at Omada's historical earnings and future estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
